3 C
New York
Tuesday, January 31, 2023

The Question Is Whether To Buy Or Not To Buy Landos Biopharma Inc. (NASDAQ: LABP)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Landos Biopharma Inc. (LABP) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0125, or 2.30%, to $0.555. The Landos Biopharma Inc. has recorded 5,170 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Landos Biopharma Provides Comprehensive Update on Clinical Development Plans.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

Landos Biopharma Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.54 and fluctuated between $0.6200 as its day high and $0.4801 as its day low. The current market capitalization of Landos Biopharma Inc. is $22.24M. A total of 2.43 million shares were traded on the day, compared to an average of 531.95K shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, LABP has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 2 SELLs from insiders. Insiders purchased 500,000 shares during that period but sold 800,000.

In the most recent transaction, RTW INVESTMENTS, LP sold 300,000 shares of LABP for 0.69 per share on Sep 23. After the transaction, the 10% Owner now owns 3,975,722 company shares.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for LABP in the last 3 months, the mean price target is $1.05 with high estimates of $2.00 and low estimates of $0.10. In terms of 52-week highs and lows, LABP has a high of $4.92 and a low of $0.21.

As of this writing, LABP has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.28 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.37 in the last quarter, which was -5.70% lower than expectations of -$0.35.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LABP is Buy with a score of 3.00. A total of 0 analysts rated the stock as Buy while 0 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles